Macquarie stock slips into the weekend — what investors watch next for ASX:MQG

Macquarie stock slips into the weekend — what investors watch next for ASX:MQG

Sydney, Jan 10, 2026, 17:09 AEDT — Market closed.

  • Macquarie Group Ltd (ASX:MQG) last closed at A$206.08, down 1.25% on Friday.
  • Australian financials logged their weakest week in seven, a Reuters report said, after a choppy session that ended with the benchmark barely changed.

Macquarie Group shares ended Friday down 1.25% at A$206.08, leaving the stock up 2.8% so far this year after the first full week of trading. The S&P/ASX 200 slipped 0.33% to 8,717.8.

That matters now because Macquarie tends to trade on a mix of rate expectations and risk appetite. When investors get jumpy about inflation, bond yields and credit spreads, the market often marks down the parts of the business most tied to trading conditions and deal flow.

One new talking point sits in its asset-management arm. PitchBook reported Macquarie Asset Management is seeking about $1 billion for its debut U.S. direct lending fund, aimed at making senior secured loans to mid-sized businesses and staying in the market through 2027. Direct lending, often called private credit, is when investors lend straight to companies rather than buying publicly traded bonds.

Macquarie had no company announcements on Saturday, ASX data show, so the next price cues for MQG are likely to come from global markets and the rates tape.

Technically, the stock has yet to close above A$210 in January and it fell as low as A$205.80 in Friday’s session after opening at A$210.00. Traders often treat round numbers like A$200 as a first “support” zone — an area where buying can show up — if the selling picks up again.

MQG is still far below its 52-week high of A$242.90 and above the low of A$160.00, leaving room for wider swings if the outlook shifts. That range sits behind the stock’s habit of moving with market conditions that can change quickly for a group that earns from banking, asset management, trading and advisory work.

But the near-term setup cuts both ways. A firmer inflation print could push out rate-cut expectations and weigh on bank valuations more broadly, while private-credit growth can turn messy if refinancing conditions tighten and defaults rise.

The calendar is the next driver: U.S. consumer prices for December are due on Jan. 13, Australia’s monthly CPI indicator is scheduled for Jan. 28, and the Reserve Bank of Australia is set to announce its Feb. 3 policy decision. The next company catalyst for MQG is its scheduled Feb. 9 update. (Bureau of Labor Statistics)

Stock Market Today

  • Vera Therapeutics Valuation Under Scrutiny After Momentum
    January 10, 2026, 5:06 PM EST. Vera Therapeutics (VERA) trades at $48.71 after a sharp rally, with a 1-month gain near 9.9% and a 3-month advance around 61.9% as investors weigh growth against clinical and financing risks. The 3-year total shareholder return runs about 7x. On a P/B of 8.7x, the stock sits above the broader US biotech average (2.7x) but below some peers (11.8x). A DCF view yields a fair value about $242.41, implying roughly an 80% discount to the current price. The company reports no revenue and a net loss of about $251.9 million. Upside depends on trial progress and funding; downside risk remains if milestones slip or financing deteriorates. Analysts' targets are higher than today's price, keeping a watchful eye on progress.
Westpac shares (ASX:WBC) in focus after bushfire relief package as rate outlook shifts
Previous Story

Westpac shares (ASX:WBC) in focus after bushfire relief package as rate outlook shifts

PLS Group (ASX: PLS) stock slips from fresh high — lithium prices jump, Jan 30 update looms
Next Story

PLS Group (ASX: PLS) stock slips from fresh high — lithium prices jump, Jan 30 update looms

Go toTop